👀 Geographic atrophy (GA) is one of the characteristics of advanced age-related macular degeneration (AMD) and can cause vision loss, even legal blindness. Yet, treatment options for GA or its progression remain limited. This NEI research investigated minocycline's potential to slow vision loss and halt GA expansion in AMD patients. Our VeriSee AMD, a TFDA-approved medical AI, makes early screening for AMD and early access to ophthalmic care possible. Together, we can improve public health of eye care! #AMD #GeographicAtrophy #EyeHealth #NEI #AcerMedical #VeriSeeAMD
Tiarnan Keenan and colleagues at the National Eye Institute (NEI) released results of a phase II clinical study looking at the drug minocycline, an antibiotic that also decreases inflammation, and its effects in slowing vision loss or expansion of geographic atrophy in people with age-related macular degeneration (AMD). Check the JAMA Ophthalmology paper: https://bit.ly/4a6aJAI
